Neuropathic orofacial pain: cannabinoids as a therapeutic avenue.

Posted on August 26, 2014 by David

“Neuropathic orofacial pain (NOP) exists in several forms including pathologies such as burning mouth syndrome (BMS), persistent idiopathic facial pain (PIFP), trigeminal neuralgia (TN) and postherpetic neuralgia (PHN).

The pathophysiology of some of these conditions is still unclear and hence treatment options tend to vary and include a wide variety of treatments including cognitive behavior therapy, anti-depressants, anti-convulsants and opioids; however such treatments often have limited efficacy with a great amount of inter-patient variability and poorly tolerated side effects.

Analgesia is one the principal therapeutic targets of the cannabinoid system and many studies have demonstrated the efficacy of cannabinoid compounds in the treatment of neuropathic pain.

This review will investigate the potential use of cannabinoids in the treatment of symptoms associated with NOP.”

http://www.ncbi.nlm.nih.gov/pubmed/25150831

http://www.thctotalhealthcare.com/category/neuropathic-pain/

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study.

Posted on August 16, 2014 by David

“Chronic neuropathic pain is often refractory to standard pharmacological treatments.

Although growing evidence supports the use of inhaled cannabis for neuropathic pain, the lack of standard inhaled dosing plays a major obstacle in cannabis becoming a “main stream” pharmacological treatment for neuropathic pain.

The objective of this study was to explore the pharmacokinetics, safety, tolerability, efficacy, and ease of use of a novel portable thermal-metered-dose inhaler (tMDI) for cannabis in a cohort of eight patients suffering from chronic neuropathic pain and on a stable analgesic regimen including medicinal cannabis…

This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a Δ9-THC pharmacokinetic profile with low interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.”

http://www.ncbi.nlm.nih.gov/pubmed/25118789

http://www.thctotalhealthcare.com/category/neuropathic-pain/

Cannabis very effective as painkiller after a major sugery

Posted on June 22, 2014 by David

Fight For medical Marijuana

“The very existence of cannabis as a substance with possible medical use is a contentious topic, to say the least. Its status as an illicit substance is hotly debated, with proponents from both sides (for and against legalization) engaged in a decades-long battle.

The status of marijuana in the United States as a Schedule I Substance under the Controlled Substances Act means not only that it is highly illegal to possess, but it is classified along the likes of cocaine, heroine, and crystal meth.

Schedule I substances are those that a) have high potential to be abused; b) have no currently accepted medical use in treatment in the United States; and c) are lacking in accepted safety in use under medical supervision.

All of these qualifiers are potentially important in classifying drugs and substances, but many people argue that marijuana does not belong in Schedule I…

Pain after surgery remains a problem in the medical community, and traditional prescribed painkillers often have unpleasant side effects as well as diminishing benefits.

Cannabis extracts work due to the cannabinoid receptors in the human brain.

Cannabinoids from marijuana help to effectively strengthen the body’s ability to reduce pain sensation.”

http://www.royalqueenseeds.com/blog-cannabis-very-effective-as-painkiller-after-a-major-sugery–n55

Cannabis very effective as painkiller after a major sugery

Cannabis as painkiller

Posted on June 22, 2014 by David

“Cannabis-based medications have been demonstrated to relieve pain.

Cannabis medications can be used in patients whose symptoms are not adequately alleviated by conventional treatment.

The clinical effect of the various cannabis-based medications rests primarily on activation of endogenous cannabinoid receptors.

Consumption of therapeutic amounts by adults does not lead to irreversible cognitive impairment.”

http://www.sciencedaily.com/releases/2012/08/120807101232.htm

http://www.thctotalhealthcare.com/category/pain-2/

Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.

Posted on May 20, 2014 by David

“The available commercial cannabinoids have a narrow therapeutic index. Recently developed peripherally restricted cannabinoids, regionally administered cannabinoids, bifunctional cannabinoid ligands and cannabinoid enzyme inhibitors, endocannabinoids, which do not interact with classic cannabinoid receptors (CB1r and CB2r), cannabinoid receptor antagonists and selective CB1r agonists hold promise as analgesics…

Expert opinion: Regional and peripherally restricted cannabinoids will reduce cannabinomimetic side effects. Spinal cannabinoids may increase the therapeutic index by limiting the dose necessary for response and minimize drugs exposure to supraspinal sites where cannabinomimetic side effects originate. Cannabinoid bifunctional ligands should be further explored. The combination of a CB2r agonist with a transient receptor potential vanilloid (TRPV-1) antagonist may improve the therapeutic index of the CB2r agonist. Enzyme inhibitors plus TRPV-1 blockers should be further explored. The development of analgesic tolerance with enzyme inhibitors and the pronociceptive effects of prostamides limit the benefits to cannabinoid hydrolyzing enzyme inhibitors.

Most clinically productive development of cannabinoids over the next 5 years will be in the area of selective CB2r agonists. These agents will be tested in various inflammatory, osteoarthritis and neuropathic pains.”

http://www.ncbi.nlm.nih.gov/pubmed/24836296

http://www.thctotalhealthcare.com/category/pain-2/

Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.

Posted on April 21, 2014 by David

“Chemotherapeutic treatment results in chronic pain in an estimated 30-40 percent of patients. Limited and often ineffective treatments make the need for new therapeutics an urgent one. We compared the effects of prophylactic cannabinoids as a preventative strategy for suppressing development of paclitaxel-induced nociception…

Our results support the therapeutic potential of cannabinoids for suppressing chemotherapy-induced neuropathy in humans.”

http://www.ncbi.nlm.nih.gov/pubmed/24742127

http://www.thctotalhealthcare.com/category/neuropathic-pain/

1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.

Posted on February 13, 2014 by David

“The relevance of CB2R-mediated therapeutic effects is well-known for the treatment of inflammatory and neuropathic pain and neurodegenerative disorders. In our search for new cannabinoid receptor modulators, we report the optimization of a series of 1,2-dihydro-2-oxopyridine-3-carboxamide derivatives as CB2R ligands…”

http://www.ncbi.nlm.nih.gov/pubmed/24518874

Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions.

Posted on February 6, 2014 by David

“Although originally described as a signalling system encompassing the cannabinoid CB1 and CB2 receptors, their endogenous agonists (the endocannabinoids), and metabolic enzymes regulating the levels of such agonists, the endocannabinoid system is now viewed as being more complex, and including metabolically related endocannabinoid-like mediators and their molecular targets as well.

The function and dysfunction of this complex signalling system in the molecular and cellular mechanisms of pain transduction and control has been widely studied over the last two decades.

In this review article, we describe some of the latest advances in our knowledge on the role of the endocannabinoid system, in its most recent and wider conception, in pain pathways, by focusing on: (1) neuron-glia interactions; and (2) emerging data on endocannabinoid cross-talk with neurotrophins, such as nerve growth factor and brain-derived neurotrophic factor.”

http://www.ncbi.nlm.nih.gov/pubmed/24494680

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.

Posted on January 16, 2014 by David

“Peripheral neuropathic pain (PNP) associated with allodynia poses a significant clinical challenge. The efficacy of Δ9 -tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray, a novel cannabinoid formulation, was investigated in this 15-week randomized, double-blind, placebo-controlled parallel group study…

These findings demonstrate that, in a meaningful proportion of otherwise treatment-resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.”

http://www.ncbi.nlm.nih.gov/pubmed/24420962

Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy.

Posted on December 24, 2013 by David

“Patients receiving paclitaxel often develop peripheral neuropathies. We found that a novel selective cannabinoid CB2 receptor agonist (MDA7) prevents paclitaxel-induced mechanical allodynia in rats and mice…

The preventive effect of MDA7 on paclitaxel-induced peripheral allodynia in rats may be associated with genes involved in signal pathways in central sensitization, microglial activation, and neuroinflammation in the spinal cord.”

http://www.ncbi.nlm.nih.gov/pubmed/24361916